Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Effect of capecitabine and melatonin on HER2+ (SK-BR-3) and HER2- (MCF7) human breast cancer cell lines

Sepideh Shayan1, Laya Takbiri Osgoei2 , Fatemeh Javani Jouni3

1Department of Biochemistry, Faculty of Biological Sciences, Islamic Azad University, Tehran, Iran; 2Department of Microbiology, Faculty of Biological Sciences, North Tehran Branch, Islamic Azad University, Tehran, Iran; 3Department of Biomedical Engineering, Faculty of Health, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.

For correspondence:-  Laya Osgoei   Email: l_takbiri@iau-tnb.ac.ir   Tel:+989057241495

Accepted: 27 June 2023        Published: 31 July 2023

Citation: Shayan S, Osgoei LT, Jouni FJ. Effect of capecitabine and melatonin on HER2+ (SK-BR-3) and HER2- (MCF7) human breast cancer cell lines. Trop J Pharm Res 2023; 22(7):1387-1393 doi: 10.4314/tjpr.v22i7.5

© 2023 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To determine the effect of melatonin in combination with capecitabine on the proliferation and induction of apoptosis in MCF-7 and SK-BR-3 breast cancer cell lines.
Methods: The MTT assay (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) was performed to investigate the effect of capecitabine and in combination with melatonin on cell lines and to determine the half-maximal concentration (IC50) and combination index. expression of apoptotic markers, Bax, Bcl-2, and caspase-3 were measured by polymerase chain reaction (PCR) after treatment.
Results: The IC50 of melatonin and capecitabine in MCF-7 and SK-BR-3 cell lines were 4.52 mM and 619.36 µg/mL, and 5.1 mM and 679.51 µg/mL, respectively. The combined use of melatonin and capecitabine significantly reduced IC50. Also, combination index (CI) values were < 1, indicating that the combination of capecitabine and melatonin has a synergistic effect. The results of gene expression also showed enhancement in the Bax/Bcl-2 ratio in melatonin-capecitabine combination compared with capecitabine alone in both cell lines.
Conclusion: Melatonin-capecitabine-induced cell death is controlled by caspase-3 and Bax/Bcl-2-dependent apoptosis. The combination of melatonin and capecitabine has a synergistic effect on both HER2+ and HER2- cells.

Keywords: Melatonin, Capecitabine, Breast cancer, MCF7, SK-BR-3, Apoptosis

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates